Clinical trials
Amyloid Cardiomyopathy clinical trials
Below are recruiting amyloid cardiomyopathy clinical trials, each written for real people, not researchers. We’re tracking 30 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06634108RecruitingPhase 1/Phase 2
Genistein for heart failure from ATTR amyloid cardiomyopathy
This trial tests whether genistein, a plant-based supplement, can help people with a specific type of heart disease called ATTR amyloid cardiomyopathy. You might join if you have heart failure with reduced pumping function and this rare protein condition.
London, OntarioAges 40–80 - NCT07240844RecruitingPhase 4
Enavogliflozin for amyloid heart disease
This study tests a drug called enavogliflozin to see if it helps people with a specific type of heart failure caused by amyloid buildup. It may improve symptoms and daily function.
SeoulAges 19 years+ - NCT05667493Enrolling by invitationPhase 3
Long-term safety follow-up for eplontersen in ATTR heart disease
This is a long-term study to check the safety of eplontersen over time in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). It is mainly for people who already took the study medication before, or who joined an earlier related study and are doing well.
Scottsdale, ArizonaAges 18 years+ - NCT07235462Recruiting
Acoramidis for heart disease due to TTR amyloidosis
This study follows people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM) who are starting treatment with acoramidis. It aims to see how well the medicine works in everyday medical practice.
HeidelbergAges 18 years+ - NCT07766135Recruiting
Liver and blood clotting in heart amyloidosis
This study looks at how the liver and blood clotting are affected in people with a type of heart disease called transthyretin amyloidosis. It may help doctors better understand and manage this condition.
Messina, SicilyAges 18 years+ - NCT06563895RecruitingPhase 3
Testing acoramidis to prevent ATTR amyloidosis in gene carriers
This trial tests a daily pill called acoramidis to see if it can prevent ATTR amyloidosis in people who carry a gene mutation but have no symptoms yet. It aims to stop the disease before it starts.
La Jolla, CaliforniaAges 18–75 - NCT02641145Recruiting
PET/MRI scans in light-chain amyloid heart disease
This study uses special PET and heart MRI scans to better understand light-chain amyloidosis affecting the heart. The scans may help researchers see how the disease behaves in different patient groups and treatment states.
Boston, MassachusettsAges 18–99 - NCT07207811RecruitingPhase 3
Coramitug for heart failure caused by ATTR amyloidosis
This trial tests a new medicine called Coramitug for people with heart failure due to ATTR amyloidosis, a condition where abnormal proteins build up in the heart. The study aims to see if Coramitug can improve heart function and quality of life.
Phoenix, ArizonaAges 18 years+ - NCT07695701RecruitingPhase 4
Heart imaging study for a new ATTR-CM treatment
This trial uses heart scans to see how the drug acoramidis affects heart structure and function in people with a specific type of heart disease called ATTR cardiomyopathy. It may help doctors understand if the treatment is working.
St Louis, MissouriAges 18–80 - NCT07298044RecruitingPhase 4
Switching from tafamidis to acoramidis for heart condition
This study checks how levels of a protein called transthyretin change in your blood when you switch from tafamidis to acoramidis. It is for people with a specific type of heart disease caused by abnormal protein buildup.
Sankt Pölten, Lower AustriaAges 18–90 - NCT07382128Recruiting
Heart MRI to Understand Hypertrophic Cardiomyopathy
This trial uses a special heart MRI to better understand different types of hypertrophic cardiomyopathy (thick heart muscle). It may help doctors tell apart various forms of the condition and guide treatment.
Bologna, BOAges 18 years+ - NCT07398950Enrolling by invitation
AI screening for a heart condition called ATTR-CM
This study uses artificial intelligence (AI) to look at your heart tests (ECG and echo) and find people who might have a specific heart muscle disease called ATTR-CM. The goal is to catch it earlier so treatment can start sooner.
New Haven, ConnecticutAges 18 years+ - NCT05697861Enrolling by invitation
Follow-up study for people previously treated with NTLA-2001
This study checks how people are doing long-term after receiving NTLA-2001 in an Intellia clinical trial. If you previously took part and agree to be followed, this may help the researchers understand lasting safety and effects.
ParisAges 18 years+ - NCT06836011Recruiting
Heart valve leakage study in a type of amyloid heart disease
This study looks at how common and how serious heart valve leaks are in people with transthyretin amyloid cardiomyopathy (a condition where abnormal protein builds up in the heart). The goal is to better understand these leaks and how they affect long-term health.
Graz, StyriaAges 18 years+ - NCT07448623RecruitingPhase 1
Testing coramitug for ATTR amyloid heart disease
This study tests a new medication called coramitug to see if it can reduce abnormal protein deposits in the heart. You will have special PET/CT scans to measure how the drug affects these deposits.
GroningenAges 60 years+ - NCT07196839Recruiting
Study of heart medication and amyloid levels over time
This study looks at how a heart medication (tafamidis) affects amyloid protein levels in the blood over time. It may help doctors understand how well the treatment works for people with a specific type of heart disease caused by amyloid buildup (ATTR-CM).
Dallas, TexasAges 30–80 - NCT07690436Recruiting
Eye imaging for detecting a type of heart disease
This study uses retinal imaging (pictures of the back of the eye) and OCT scans to look for signs of a specific heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). It may help doctors find this condition with an eye exam instead of more invasive tests.
Palo Alto, CaliforniaAges 18 years+ - NCT06101108Recruiting
Early heart screening in back surgery patients
This trial checks people having back surgery for spinal stenosis to see if they have an early sign of heart amyloidosis (a protein buildup in the heart). The goal is to find this condition early so it can be treated before it causes problems.
BrugesAges 60 years+ - NCT06291805Recruiting
Understanding wtATTR-CM heart disease (TRACE 1)
This study aims to better understand a type of heart disease called wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM). It will compare people with this condition to a control group without known heart disease to identify key features.
Aarhus, Arrhus NAges 18 years+ - NCT07560306RecruitingPhase 3
New Heart Scan to Detect Blood Clots in Amyloid Heart Disease
This study tests a new type of imaging scan ([64Cu]FBP8 PET) to detect blood clots that may form in the heart's left atrial appendage (a small pouch in the heart) in patients with amyloid cardiomyopathy (a disease where abnormal protein builds up in heart muscle) who also have irregular heartbeat. The scan may help doctors catch clots earlier and prevent strokes.
Boston, MassachusettsAges 18 years+ - NCT04776824Recruiting
Swiss registry for people with amyloidosis and possible heart involvement
This trial is a registry that collects health information from people with amyloidosis, including cases where the heart may be involved. Sharing your medical details can help researchers learn how this condition affects patients and may guide future care.
BaselAges 18 years+ - NCT05489549Recruiting
Study of heart amyloid risk in people with TTR gene variants
This study looks at people who carry certain TTR gene variants, which can cause a specific type of heart amyloid buildup. It also includes people with symptoms, to understand how the condition develops and how it may be monitored.
New York, New YorkAges 30–80 - NCT05797857Recruiting
Exercise program for transthyretin heart amyloidosis
This trial studies whether a structured exercise training program is safe and helpful for people with transthyretin (ATTR) cardiac amyloidosis. It may help improve fitness and daily functioning, and it may also compare groups for specific eligibility needs.
Boston, MassachusettsAges 60–90 - NCT06251778Recruiting
National study of ATTR heart amyloid patients on tafamidis
This study follows patients with a specific type of heart amyloidosis (wild-type ATTR) who are taking or could start the drug tafamidis. It aims to learn more about how the condition and treatment affect people over time.
PaviaAges 18–99
Hear when a new Amyloid Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for amyloid cardiomyopathy?
- Yes. Clin2 currently lists 30 recruiting amyloid cardiomyopathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a amyloid cardiomyopathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a amyloid cardiomyopathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.